Behind Trillium’s TTI-622’s Complete Response In Advanced DLBCL (ASCO Preview)

The following article serves to prepare readers for first-in-human data for Trillium’s CD47-blocker, TTI-622, in patients with advanced relapsed or refractory lymphoma. The company recently revealed a complete response in DLBCL. Below, we review lymphoma/DLBCL; Trillium’s drug, TTI-622; competition; and what to look for in upcoming ASCO data. Lymphoma overview Lymphoma describes a series of […]
To access this post, you must purchase Prime Membership or Plus Membership.

This information is protected.

%d bloggers like this: